Popular Trials
Stem Cell Therapy
Stem Cell Therapy for Retinal and Optic Nerve Disorders
This trial will use stem cells from patients' own bone marrow to treat severe vision loss caused by retinal or optic nerve damage. The stem cells will be injected into the eye to help repair the damaged tissues. SCOTS is the largest ophthalmology stem cell study registered at the National Institutes of Health, using autologous bone marrow-derived stem cells for retinal and optic nerve diseases.
Gene Therapy
RGX-314 Gene Therapy for Age-Related Macular Degeneration
This trial is evaluating a potential new treatment for a disease that causes vision loss. The current standard of care for this disease requires life-long, repeated injections to maintain efficacy, but this new treatment would only require a single injection.
Phosphodiesterase Type 5 (PDE5) Inhibitor
Sildenafil for Choroidal Ischemia
This trial is testing if Sildenafil can help patients with certain eye conditions by improving blood flow in the eye. The goal is to slow down vision loss and reduce the need for frequent treatments. Sildenafil, commonly known as Viagra, is primarily used to treat erectile dysfunction but has been studied for its effects on ocular blood flow and potential neuroprotective benefits in various eye conditions.
Stem Cell Therapy
Stem Cell Therapy for Age-Related Macular Degeneration
This trial is for adults 50+ who are losing their vision due to dry age-related macular degeneration. A new treatment, ASP7317, which is a specially created type of cell derived from human stem cells, will be injected into the macula of the eye in an effort to slow or reverse atrophy.
Complement Inhibitor
Danicopan for Age-Related Macular Degeneration
This trial is testing a medication called danicopan to see if it can help people with a specific type of eye disease called Geographic Atrophy, which is related to Age-related Macular Degeneration. The study will check how well the medication works, how safe it is, and how the body handles it.
Monoclonal Antibodies
SUSVIMO for Age-Related Macular Degeneration
This trial will assess the response to treatment with SUSVIMO given every 24 weeks in patients with nAMD who have been previously treated with anti-VEGF agents. A substudy will evaluate the impact of SUSVIMO on corneal endothelial cells.
Popular Filters
Trials for Age-Related Macular Degeneration Patients
Behavioural Intervention
Scotoma Awareness Training for Low Vision
This trial tests a new training method for older adults with Macular Degeneration, a condition causing central vision loss. The training uses a simulated blind spot to help patients become aware of their vision loss and develop new ways to see better. By making patients aware of their blind spot, the training aims to improve their vision and daily functioning. Eccentric viewing training has been shown to improve near visual acuity, reading speed, and daily functioning in people with central vision loss.
Brain Stimulation
Active tDCS for Age-Related Macular Degeneration
This trial is testing whether a-tDCS, a kind of brain stimulation, can be combined with perceptual learning to improve the ability of people with age-related or juvenile macular degeneration to read words on a computer screen.
Trials for AMD Patients
Behavioural Intervention
Scotoma Awareness Training for Low Vision
This trial tests a new training method for older adults with Macular Degeneration, a condition causing central vision loss. The training uses a simulated blind spot to help patients become aware of their vision loss and develop new ways to see better. By making patients aware of their blind spot, the training aims to improve their vision and daily functioning. Eccentric viewing training has been shown to improve near visual acuity, reading speed, and daily functioning in people with central vision loss.
Brain Stimulation
Active tDCS for Age-Related Macular Degeneration
This trial is testing whether a-tDCS, a kind of brain stimulation, can be combined with perceptual learning to improve the ability of people with age-related or juvenile macular degeneration to read words on a computer screen.
Trials for ABCA4 Positive Patients
Vitamin A Derivative
ALK-001 for Stargardt Disease
This trial tests a special type of vitamin A called ALK-001 to see if it can safely slow down vision loss in people with Stargardt disease by reducing harmful substances in the eye. ALK-001 is designed to reduce the accumulation of toxic substances in the retina, which are associated with vision loss in Stargardt disease.
Complement Factor C5 Inhibitor
Zimura for Stargardt Disease
This trial is testing an eye injection medication to help people with Stargardt disease, a genetic condition that leads to vision loss. The medication aims to block harmful processes in the eye to prevent further vision loss.
Tinlarebant for Stargardt Disease
This trial is testing a medication called tinlarebant to see if it can slow down eye damage in teenagers with a condition called STGD1. About 90 participants will take tinlarebant for an extended period. The goal is to see if tinlarebant can help prevent their vision from getting worse.
Phase 3 Trials
Vascular Endothelial Growth Factor (VEGF) Inhibitor
OPT-302 + Aflibercept for Age-Related Macular Degeneration
This trial will compare a new treatment to a sham (fake) treatment in order to see if the new treatment is effective. The primary efficacy will be determined at Week 52, meaning that's how long the trial will last.
Gene Therapy
RGX-314 Gene Therapy for Wet Age-Related Macular Degeneration
This trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. It aims to help the eye make its own medicine to stop harmful blood vessels from causing vision loss. This could reduce the need for regular injections. RGX-314 modifies the retina's cells to create a treatment that may only be needed once.
Complement Inhibitor
Pegcetacoplan for Age-Related Macular Degeneration
This trial is testing a medication called pegcetacoplan to see if it is safe and effective for people with a severe eye condition called geographic atrophy, which is related to age-related macular degeneration. The medication aims to protect the eye by blocking harmful immune responses. Pegcetacoplan has shown an acceptable safety profile in previous studies for geographic atrophy.
Trials With No Placebo
Behavioural Intervention
Scotoma Awareness Training for Low Vision
This trial tests a new training method for older adults with Macular Degeneration, a condition causing central vision loss. The training uses a simulated blind spot to help patients become aware of their vision loss and develop new ways to see better. By making patients aware of their blind spot, the training aims to improve their vision and daily functioning. Eccentric viewing training has been shown to improve near visual acuity, reading speed, and daily functioning in people with central vision loss.
Anti-VEGF Monoclonal Antibody
Zifibancimig for Age-Related Macular Degeneration
This trial is testing a new treatment called zifibancimig for people with a serious eye condition known as neovascular age-related macular degeneration (nAMD). The treatment is given either as an injection into the eye or through a small implant. It works by stopping harmful blood vessels from growing in the eye, which can help protect or improve vision.
View More Related Trials
Frequently Asked Questions
Introduction to age related macular degeneration
What are the top hospitals conducting age related macular degeneration research?
When it comes to revolutionary clinical trials aimed at combating age-related macular degeneration (AMD), several hospitals are leading the charge. In Reno, Sierra Eye Associates takes the spotlight with an impressive portfolio of 10 ongoing AMD trials and a total of 48 completed studies dedicated to this condition. Since conducting their first trial in 2013, Sierra Eye Associates has been at the forefront of exploring innovative treatments for AMD. Meanwhile, Cumberland Valley Retina Consultants in Hagerstown is making significant strides as well, currently undertaking nine active clinical trials focused on AMD and having completed 16 previous investigations since their inaugural study in 2012.
Texas also proves its commitment to advancing knowledge about AMD through two prominent institutions: Retina Consultants of Texas in Bellaire and The Woodlands. Both locations actively engage in research efforts with nine and eight ongoing clinical trials respectively for AMD. With a combined history encompassing 41 studies between them dating back to their earliest recorded trial in 2015 (Bellaire) and more recently starting from only three years ago (The Woodlands), these institutions demonstrate dedication towards finding new approaches to managing this debilitating eye disease.
Back on the East Coast, Ophthalmic Consultants of Boston plays a vital role by conducting seven active clinical trials targeting age-related macular degeneration while contributing valuable insights from their extensive experience spanning over four decades - they have conducted an impressive total of43 such studies since embarking upon their first investigation into this condition way back in1999.
These hospitals' commitment showcases not only advancements made thus far but also fosters hope for millions impacted by age-related macular degeneration worldwide. As science continues evolving alongside medical expertise within these top-tier facilities, each breakthrough serves as a stepping stone toward improved management and potential cures for this sight-threatening ailment
Which are the best cities for age related macular degeneration clinical trials?
When it comes to age-related macular degeneration clinical trials, several cities show promising advancements in research and treatment options. Phoenix, Arizona leads the way with 32 active trials, investigating therapies like RGX-314, IONIS-FB-LRx, and ADVM-022. Austin, Texas closely follows with 29 ongoing studies focused on IONIS-FB-LRx, RGX-314, and Faricimab. Boston, Massachusetts and Philadelphia, Pennsylvania both have 25 active trials each that explore treatments such as RGX-314 Dose 2 and PEGCETACOPLAN (APL-2). Lastly Baltimore,Maryland offers a location where 24 active trials are investigating potential breakthroughs including RGX-314 and JNJ-81201887 High dose. These cities provide individuals with age-related macular degeneration access to cutting-edge clinical trials that hold valuable promise for improved vision outcomes.
Which are the top treatments for age related macular degeneration being explored in clinical trials?
Clinical trials are paving the way for advancements in the treatment of age-related macular degeneration (AMD). The top contenders include ALK-001, currently undergoing two active trials and contributing to a total of two AMD clinical trials since its introduction in 2015. Another promising candidate is RGX-314, which has shown potential with two ongoing trials and four all-time AMD studies since its listing in 2017. Also making waves is RGX-314 Dose 2, newly listed in 2020 but already making an impact with two ongoing AMD trials. These treatments signify hope for individuals affected by this debilitating eye condition as researchers bring us closer to effective solutions through their tireless efforts in clinical research.
What are the most recent clinical trials for age related macular degeneration?
Promising clinical trials have emerged in the field of age-related macular degeneration, offering hope for patients grappling with this condition. One notable trial is NG101 Gene Therapy Group 1, which has entered Phase 2 after showing encouraging results in Phase 1. Another study investigates an experimental treatment involving low-dose escalation aimed at addressing the progression of macular degeneration. Additionally, KH631 Dose 1 and CT1812 200 mg have demonstrated potential benefits for individuals affected by age-related macular degeneration. As these innovative trials continue to progress through different phases, they hold promise for improving outcomes and quality of life for those battling this vision-threatening disease.
What age related macular degeneration clinical trials were recently completed?
Several recent clinical trials have made significant progress in the field of age-related macular degeneration (AMD). In May 2022, Sandoz successfully completed a trial investigating SOK583A1. Additionally, Kodiak Sciences Inc. concluded their research on KSI-301 in June 2021, while Maturi, Raj K., M.D., P.C. wrapped up their study on RBM-007 Injectable Solution during the same month. These trials represent important milestones in our ongoing efforts to understand and find effective treatments for AMD, offering hope to individuals affected by this condition.